Additionally, the methylation of the PD-L1 promoter has been shown to negative correlate with its gene expression and is clinically associated with survival, including from prostate cancer, colorectal cancer, acute myeloid leukemia and melanoma [22,23,24,25]. This evidence concerns the gene CD274 and prostate cancer.